Acute graft-versus-host disease (aGVHD) has been classified according to the Seattle criteria as grades 0, I, II, III, and IV for 20 years. The predictive value of such detailed grading is a matter of debate; publications usually report GVHD as present or absent or as absent, moderate, or severe. The Working Party Chronic Leukemia of the European Group for Bone Marrow Transplantation analyzed data of 1,294 pa tients transplanted from an allogeneic donor for chronic my elogenous leukemia (CML) in first chronic phase and tested the predictive value of aGVHD grading for the following end points: day 100 mortality (D100M), transplant-related mor tality (TRM), relapse incidence (Rl), leukemia-free survival (LFS), and survival (SURV). aGVHD w as absent in 462 pa tients (35.7%), grade I occurred in 335 (25.8%), grade II in 264 (20.5%), grade III in 110 (8.5%), and grade IV in 123 pa tients (9.5%). A total of 297 patients (23%) died within 100 days, 495 patients (38%) died of any TRM, and 100 patients (8%) died of relapse. D100M according to grades 0, I, II, III, and IV was 17%, 13%, 19%, 38%, and 70%, respectively, with significant difference between 0-II versus lll-IV. TRM was 28%, 27%, 43%, 68%, and 92%, respectively, with a distinct separation between 0-I versus ll-IV. Rl showed a continuous decrease of 37%, 30%, 23%, 18%, and 8%, respectively, with increasing aGVHD. LFS w as 45%, 51%, 44%, 26%, and 7%, respectively, and was best for patients with grade I aGVHD. This finding was also reflected in a better overall survival (60%, 64%, 53%, 30%, and 8%, respectively). The better LF S for grade I aGVHD patients compared with patients with grade 0 or II aGVHD was confirmed (P -.05) in a multivariate analysis. These data document the value of the present 5-point grading of aGVHD, ie, different outcome is observed depending on endpoint analyzed. Restricting information about aGVHD to presence or absence is not warranted. 
The data were collected by questionnaire containing information on donor and recipient identity, sex, age, and histocompatibility. Moreover, patient data were available on primary disease, transplant procedure, conditioning, GVHD prevention method, and outcome. The data were collected annually and updated as of January 1, 1993, For logistic reasons, not all teams reported all their patients. Some teams ceased to report, whereas some only began reporting at a later stage. The participating institutions are listed in the Appendix.
Patients. The present analysis concentrates on 1,294 with CML transplanted in first chronic phase of their disease with bone marrow from an allogeneic donor. Identical twin transplants and patients with second transplants were excluded. Table 1 summarizes the patient and transplant characteristics in regard to age, donor recipient sex combination, GVHD prevention method, donor source, year of transplant, and interval from diagnosis to transplant. Of the 1,294 patients with CML, 58% were male and 42% were female. Male patients receiving female bone marrow represent 330 cases (26%). The median age was 33 years, with a range from 0.5 to 58 years. One -two patients ) were 20 years or younger and 1,142 patients were older than 20 years. The donor was an HLA-identical sibling in 90% of the patients (n -1,160) and a nonidentical related or unrelated donor in 10% (n = 134). For 30% of all patients (n = 385), donor marrow was T-cell depleted as method of GVHD prevention. Fifty-five percent of transplants were performed before 1988 and 45% between I98K and 1990. The interval from diagnosis to transplant was ssl year in From Statistical analysis. Discrete variables in cross-tables and inci dence of aGVHD (grade 0 v 1 + II + III + IV) in Table 1 was analyzed with the x ' lest. Severity was compared for the different categories of age, sex, GVHD prevention method, and year of BMT by the nonparametric Mann-Whitney test and for the donor source and interval from diagnosis to transplant by the Kruskall-Wallis test. The inlluenee of different grades of aGVHD on DIOOM was ana lyzed with a logistic regression.7 For each of the grades I or higher, relative risks with respect to grade 0 were assessed. Adjustments are made for the covariables sex match, age, donor source, T-eell depletion, year of BMT, and interval from diagnosis to transplant, as listed in Table 1 . Similar analyses were performed for the other endpoints using Cox regression. To assess the influence of moderate aGVHD on relapse and LFS, the same analyses were repeated but restricted to the 1,061 patients with grade 0 , 1, or II aGVHD. Relapse incidence was also compared in a trend analysis.
All analyses were performed with the SPSS computer program (SPSS Inc, Chicago, IL). Two hundred ninety patients (23%) died within 100 days of transplant; 15 patients were censored within 100 days. A total of 495 patients (38%) died of TRM and 236 patients (18%) relapsed, 100 (8%) of whom died.
RESULTS

Follow
Incidence and severity of aGVHD. Although 462 pa tients (36%) never had any signs of aGVHD, 832 patients (64%) showed grades I to IV; 497 (38%) had grade II or higher aGVI-ID. The individual grades are listed according to age, sex, GVI-ID prevention method, donor source, and year of BMT (Table 1 ). Incidence and severity were similar in the two sex-matched categories and two age classes. There were large and significant differences in incidence and sever ity of the aGVHD grades for GVI-ID prevention and donor source. Patients with T-cell-depleted bone marrow had less GVHD and patients with donors other than HLA-identical siblings had more frequent and more severe aGVHD. There was no difference in severity of GVI-ID in the two time cohorts, but a slightly larger number o f patients transplanted before 1988 had no GVHD. This coincides with the time period of more T-cell depletion.
Influence of acute GVHD on D100M, TRM, RI, LFS, and SURV. The presence and severity of aGVI-ID have a strong impact on D100M, TRM, RI, LFS, and SURV (Fig 1 and  Table 2 ). Patients with no GVHD have lower D100M and TRM but higher RI than do patients with GVHD. There is an increase in D100M and TRM with increasing aGVHD Fig 1) . D100M increases significantly from grade III onwards; TRM increases already from grade II GVHD. In contrast, RI decreases gradually with each grade. Because of this discordant effect of TRM and RI, LFS and SURV are best for patients with grade I aGVHD. These findings were consistent for all patients or when patients were analyzed separately in subgroups for age, sex, or donor type. Therefore, data for all patients were analyzed together. Table 3 gives the quantitative analysis of the influence of aGVHD grade by logistic regression with In addition to the detailed 5-grade analysis, a series of two group settings for aGVHD absent or present were com pared in Table 4 . In both group settings the low grades were significantly different from the high grades; the only exception being one analysis of the relapse incidence (grade Relative risks are with respect to grade 0 of aGVHD and with adjust ments for age, sex match, T-cell depletion, donor source, year of BMT, and interval from diagnosis to transplant GRATW OHL ET AL The predictive value of the aGVHD grading for mortality rate already described by Glucksberg et al8 (grade 0 GVHD, 44%; I, 43%; II, 80%; III, 91%; IV, 90%) with best survival for patients with grade I has re mained, but the outcome has improved since except for grade IV. This finding can be explained by the fact that grade IV is mainly assigned retrospectively to patients who die with aGVHD within 100 days (grade 0 GVHD, 39%; I, 32%; II, 45%; III, 64%; IV, 93%).
The findings on incidence and severity in this study con firmed earlier reports, but also showed unexpected findings. aGVHD is clearly more frequent and more severe in patients receiving nonidentical family or unrelated transplants. As expected, the same holds true for patients given non-Tcell-depleted transplants. In contrast, we observed the same incidence and severity of aGVHD in patients younger than 20 years compared with older than 20 years. The effect of age on GVHD described previously',,l° might be lost in the present patient population because only a few younger pa tients (12% < 2 0 years) are reported. Interestingly, similar incidence and severity of GVHD in younger patients, TRM was lower than in older patients. This means that younger patients tolerate aGVHD and its treatment belter. A similar observation concerns male patients receiving female donor marrow. They have the same incidence and severity of aG VHD as other patients, but, as previously reported, a higher TRM.11 Factors other than aGVHD must account for the higher TRM.
With the introduction of new GVHD prevention methods, such as cyclosporin and T-cell depletion and the recognition Analysis restricted to 1,061 patients with grade 0, I, or II.
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